Kornimate/medical-research-clean huggingface dataset:
determination and comparison of short-term effectiveness of three methods used for recognition of arrhythmias in people with different degrees of medical training (advanced life support workshop participants-als): randomized controlled educational experiment.

Conditions: Arrhythmias

Summary: background: arrhythmia recognition is a fundamental skill for the provider of advanced life support (als). acquire it is difficult, leading to the birth of systematic methods in an attempt to simplify and optimize, however, it has not compared the effectiveness among the three methods with more evidence among professionals with varying degrees of medical training (als workshop participants). objective: to determine and compare the effectiveness of the three most widespread and with more evidence systematic methods (10, 6 and 4 steps) for the recognition of arrhythmias in a short-term and its perceived easiness among als workshop participants. methods / design: educational cuasi experimental trial with pre and post intervention measurement, blind, with randomized allocation, in 84 als workshop participants. three systematic methods to recognize arrhythmias will be taught and their effectiveness to diagnose in a short-term and its perceived easiness will be measured and compared.


Eligibility criteria:
inclusion criteria: * • health professionals * attend a course in advanced life support in cali (colombia), during the study period. * voluntarily accept to participate in the study exclusion criteria: * no
a phase i trial of alloreactive cell infusion following transplantation of haplotype cells in patients with myeloid malignancies

Conditions: Leukemia, Myeloid, Acute; Leukemia, Lymphoid; Myelodysplastic Syndromes; Leukemia, Myelogenous, Chronic

Summary: the purpose of this study is to determine the maximum tolerated dose of alloreactive nk cells that can be transfused following stem cell transplant.


Eligibility criteria:
inclusion criteria: * patients must have histologically documented aml, all, mds, cml, * identification of haploidentical donor * lvef \> 45% corrected * dlco \> 50% predicted * serum creatinine \<= 2 mg/dl * bilirubin \< 2 x uln * ast, alt \< 2 x uln * age ≤ 65 years * performance status 0-1 exclusion criteria: * patients relapsing \<6 months after autologous sct are not eligible. * patients with active infections requiring oral or intravenous antibiotics are not eligible for enrollment until resolution of infection * no hiv disease * non-pregnant and non-nursing

Keywords: myeloid malignancies bone marrow transplant aml all mds cml
a single dose study to evaluate the pharmacokinetics of acoramidis modified release formulations in healthy subjects

Conditions: Amyloidosis

Summary: this is a single centre, open-label, 5-period study in healthy male and non-pregnant and non-lactating healthy female subjects.

it is planned to enroll 14 subjects who will receive single oral doses of active imp in a sequential manner over 5 periods, with a minimum of 7days between dosing in each period.

Eligibility criteria:
inclusion criteria: * healthy males or non-pregnant, non-lactating healthy females * body mass index (bmi) of 18.0 to 32.0kg/m² and a body weight\>50kg as measured at screening * must be willing and able to communicate and participate in the whole study * must provide written informed consent * must agree to adhere to the contraception requirements exclusion criteria: * subjects who have received any imp formulation in a clinical research study within the 90 days prior to period 1, day 1 * history of any drug or alcohol abuse in the past 2 years * subjects with pregnant or lactating partners * clinically significant abnormal clinical chemistry, haematology or urinalysis as judged by the investigator. subjects with gilbert's syndrome are allowed. * history of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder, as judged by the investigator * presence or history of clinically significant allergy requiring treatment, as judged by the investigator. hay fever is allowed unless it is active * subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than up to 4g of paracetamol per day or hrt/hormonal contraception) in the 14 days before first imp administration.
national marrow donor program long-term donor follow-up

Conditions: Hematologic Neoplasms

Summary: this is an observational study of unstimulated bone marrow (bm) and filgrastim-mobilized peripheral blood stem cell (pbsc) donors. the primary goal is to evaluate the hypothesis that the incidence of targeted malignant, thrombotic and autoimmune disorders after unrelated hematopoietic stem cell donation are similar between unstimulated bm and filgrastim-mobilized pbsc donors.

this is an observational study of unstimulated bone marrow (bm) and filgrastim-mobilized peripheral blood stem cell (pbsc) donors. the primary goal is to evaluate the hypothesis that the incidence of targeted malignant, thrombotic and autoimmune disorders after unrelated hematopoietic stem cell donation are similar between unstimulated bm and filgrastim-mobilized pbsc donors. donors will undergo biennial surveys until study completion. cases of targeted disorders will be reviewed by the medical monitors to confirm the veracity of the report.

Eligibility criteria:
inclusion criteria: 1. unrelated donor who donated either unstimulated bm or filgrastim-mobilized pbsc between july 1, 1999 and approximately five years post study activation. 2. unrelated donor who received at least one injection of filgrastim or more, but did not donate filgrastim-mobilized pbsc between july 1, 1999 and approximately five years post study activation. 3. donation was managed by a u.s. nmdp donor center. 4. signed informed consent for participation in this long-term donor follow-up study. concurrent enrollment on other studies is permitted. exclusion criteria: 1. unrelated donor who donated filgrastim-mobilized bone marrow. 2. donation was managed by a non-u.s. donor center. 3. donor is unable to verbally communicate in any of the following languages: english, spanish, mandarin chinese, cantonese chinese, vietnamese, korean, or portuguese.

Keywords: malignant myeloid hematologic disorders filgrastim long term incidence donors who received and in those who did not receive filgrastim.
efficacy and safety of heme-iron polypeptide on improvement of anemia

Conditions: Anemia

Summary: the investigators performed a 4-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of heme-iron polypeptide on improvement of anemia. the investigators measured improvement of anemia parameters , including hemoglobin, transferrin saturation, serum iron, and ferritin, and monitored their blood pressure.


Eligibility criteria:
inclusion criteria: * males and females 19-60 years old * hemoglobin concentration less than 13g/dl(men), 12g/dl(women) * able to give informed consent exclusion criteria: * allergic or hypersensitive to any of the ingredients in the test products * history of reaction to any of the test products or of gastrointestinal diseases such as crohn's disease or gastrointestinal surgery * participation in any other clinical trials within past 2 months * history of alcohol or substance abuse * laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study * pregnant or lactating women etc.
evaluation of immune response against human papillomavirus (hpv)in patients with metastatic cancer of the anal canal

Conditions: Metastatic Anal Canal Cancer; Human Papillomavirus

Summary: complete response is a rare event in metastatic anal cancer in the case of unresectable recurrence after radiochemotherapy. in the university hospital center of besançon, 8 patients with metastatic anal cancer were treated between 2005 and 2008 by 6 cycles of chemotherapy including taxane: dcf (docetaxel, cisplatin and 5-fluorouracil. in more than 90% of cases, anal cancers are related to human papilloma virus (hpv) infection, that is the case of this patients for which hpv16 (human papillomavirus type 16) genotype was identified within the tumor samples. the hypothesis is that an anti-hpv response immune could be generated by chemotherapy with dcf and contributed to the elimination of the tumour cells and to the increase of complete responses. the aim to this study is to analyze immune response against hpv in this patients in complete response.


Eligibility criteria:
inclusion criteria: * ecog performance status ≤ 1 * patient with metastatic anal cancer hpv+ * presence of a measurable target lesion according to radiological criteria (recist v1.1) * patient with more than 12 months of complete remission of metastatic anal cancer according to radiological criteria (recist v1.1)after treatment by dcf regimen (docetaxel, cisplatin and 5-fluorouracil) exclusion criteria: * pregnancy or lactation * patient with any medical or psychiatric condition or disease which would make the patient inappropriate for entry into this study.
exercise adherence in home-based cardiac rehabilitation

Conditions: Coronary Artery Disease

Summary: the study will investigate the influencing factors of exercise adherence of home-based cardiac rehabilitation in patients with coronary artery disease.

the study will conduct a quantitative questionnaire survey. patients with coronary artery disease in home-based cardiac rehabilitation will receive investigation of the influencing factors of exercise adherence.

Eligibility criteria:
inclusion criteria: * diagnosis of coronary artery disease; * age ≤75 years old; * participated in home-based cardiac rehabilitation ≥12 weeks; * volunteer to participate in this study. exclusion criteria: * have other serious acute or chronic diseases; * have severe audio-visual or speech impairments that may affect understanding and answering questions.

Keywords: coronary artery disease home-based cardiac rehabilitation exercise adherence
multi-parametric imaging of the knee in obese patients with knee osteoarthritis; weight maintenance

Conditions: Osteoarthritis; Obesity

Summary: this is a substudy to a randomised trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis (nct02905864). in the parent trial, patients will be subjected to an 8-week diet intervention phase including a low-calorie diet and dietetic counseling, after which patients will be randomised to receive either liraglutide 3 mg or liraglutide 3 mg placebo as an add-on to dietetic guidance on re-introducing regular foods and a focus on continued motivation to engage in a healthy lifestyle. this substudy aims to investigate the impact of, and subsequent change of, joint inflammation, articular cartilage composition, overall knee morphology, and clinical symptoms, in obese patients with knee osteoarthritis following a randomisation to liraglutide 3 mg or liraglutide 3 mg placebo treatment between weeks 0-52.


Eligibility criteria:
inclusion criteria: * same as parent trial (nct02905864) further exclusion criteria: * same as parent trial (nct02905864) * usual exclusion criteria for mri (i.e. pacemakers etc.)

Keywords: magnetic resonance imaging dynamic contrast enhanced mri liraglutide 3 mg liraglutide obesity osteoarthritis
targeted adherence intervention to reach glycemic control with insulin therapy for patients with diabetes

Conditions: Diabetes

Summary: the purpose of this study is to evaluate three pharmacist-outreach strategies for improving adherence to insulin among individuals with diabetes. the three approaches are equivalently-priced but vary by degree of targeting and intervention intensity.

in an era of rapidly growing healthcare costs, due to in large part to the increasing burden and complexity of chronic disease management, targeting outreach to patients who are most likely to benefit from them and tailoring interventions to individual patient needs, represent important opportunities to maximize healthcare value. the targeted adherence intervention to reach glycemic control with insulin therapy for patients with diabetes (targit-dm) trial is a pragmatic, intention-to-treat, randomized-controlled study that will evaluate the impact of three equivalently-priced strategies to improve insulin persistence and glycosylated hemoglobin \[hba1c\] control among patients with diabetes on insulin. the interventions in each of the three study arms will consist of educational mailings and telephonic pharmacist outreach. the pharmacists will assess and address potential barriers to insulin adherence and optimal glycemic control. the three study arms will employ differ both in regards to which patients are targeted and the intensity of the engagement strategy used. the low intensity intervention in arm 1 will be deployed to all subjects randomized to that arm. the moderate and high intensity interventions will be delivered to focused populations within arms 2 and 3, respectively, as defined by poor disease control and/or predicted risk of non-adherence. the interventions provided in the moderate and high intensity arms will also include feedback to the patient's provider, as needed, and potential enrollment in a text messaging program. patients in these two arms who are not targeted will receive usual care. the study population for this trial will consist of members enrolled in commercial insurance provided by horizon blue cross blue shield of new jersey. insurance claims data will be used to apply the inclusion and exclusion criteria. eligible patients will be randomized into one of three arms, stratified by baseline availability of hba1c and a valid telephone number.

Eligibility criteria:
inclusion criteria: * commercially-insured individuals receiving medical and pharmacy health insurance benefits from horizon blue cross blue shield of new jersey * at least 3 months of continuous enrollment prior to randomization * at least 1 prescription for basal insulin, 6 months prior to randomization * type 2 diabetes diagnosis exclusion criteria: * patients with medicaid or medicare as primary insurance

Keywords: insulin persistence telepharmacy
a study of an investigational study drug for benign prostatic hyperplasia (0906-140)

Conditions: Benign Prostatic Hyperplasia

Summary: the purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with benign prostatic hyperplasia.


Eligibility criteria:
inclusion criteria: * patients with benign prostatic hyperplasia exclusion criteria: * patients who are suspected to be suffering from prostatic cancer
popliteal artery entrapment syndrome & transcutaneous oxymetry

Conditions: Popliteal Entrapment Syndrome

Summary: aim of the study is to test the feasibility of transcutaneous oxygen pressure (tcpo2) recording in the diagnosis of popliteal entrapment syndrome (pes) in 30 patients with suspected pes and 30 asymptomatic control heathy subjects

patients suspected of pes and healthy cpontrols after detailled explanation of the protocol will have a recording of tcpo2 on both calves and will perform a series of elevation on foot in the standing position.

Eligibility criteria:
inclusion criteria: * age over 18 years * insurance company alffiliation symptoms consistent with pes (patients) or absence of symptoms (controls) exclusion criteria: * refuse to participate exclusion period from another protocole

Keywords: diagnosis peripheral artery disease sports
fludarabine, cyclophosphamide, and alemtuzumab in treating patients with recurrent or metastatic renal cell carcinoma (kidney cancer) undergoing allogeneic stem cell transplantation

Conditions: Kidney Cancer

Summary: rationale: drugs used in chemotherapy, such as fludarabine and cyclophosphamide, use different ways to stop cancer cells from dividing so they stop growing or die. peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. sometimes the transplanted cells can reject the body's normal tissues. alemtuzumab and tacrolimus may prevent this from happening. purpose: phase ii trial to study the effectiveness of combining fludarabine and cyclophosphamide with alemtuzumab in treating patients who are undergoing allogeneic stem cell transplantation for recurrent or metastatic renal cell carcinoma (kidney cancer).

objectives: * determine the safety and feasibility of fludarabine, cyclophosphamide, and alemtuzumab in patients with recurrent or metastatic renal cell carcinoma undergoing hla-matched allogeneic stem cell transplantation. outline: this is a pilot, multicenter study. * conditioning: patients receive fludarabine iv over 30 minutes on days -6 to -2, cyclophosphamide iv over 2 hours on days -6 and -5, and alemtuzumab iv on days -4 to -2. * allogeneic transplantation: allogeneic stem cells are infused on day 0. patients receive graft-vs-host disease prophylaxis with tacrolimus iv or orally for approximately 30 days. patients are followed weekly for 100 days and then at 6, 12, 18, 24, 36, 48, and 60 months after transplantation. projected accrual: a total of 20 patients (10 with hla-identical related donors and 10 with matched unrelated donors) will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of recurrent or metastatic renal cell carcinoma * failed interleukin-2 (il-2)-based therapy or intolerant to il-2 * clinically evident and followable disease * availability of 1 of the following compatible donors: * related hla-identical or 1-ag mismatched donor * unrelated hla-a, b, drb1-matched donor patient characteristics: age * any age performance status * karnofsky 70-100% life expectancy * no concurrent illness that severely limits life expectancy hematopoietic * not specified hepatic * no episode of hepatitis within the past month * no evidence of chronic active hepatitis or cirrhosis renal * creatinine no greater than 2 mg/dl cardiovascular * lvef at least 40% * no uncontrolled arrhythmias * no symptomatic cardiac disease pulmonary * fev_1, fvc, and dlco at least 50% of predicted (unless due to metastatic disease) other * not pregnant * negative pregnancy test * fertile patients must use effective contraception during and for 3 months after study participation * no active infection * hiv negative prior concurrent therapy: biologic therapy * see disease characteristics chemotherapy * not specified endocrine therapy * not specified radiotherapy * not specified surgery * not specified

Keywords: stage iv renal cell cancer recurrent renal cell cancer
dry needling for spasticity in stroke

Conditions: Stroke; Muscle Spasticity

Summary: the study team is recruiting 20 adults with spasticity due to chronic stroke and 20 adults with no neurological injuries for a 2 day study. in people with chronic stroke, one of the most common and disabling problems is spasticity (increased muscle tone or muscle stiffness). the purpose of this research study is to examine effects of dry needling on the nervous system (pathways between the muscle, spinal cord, and brain) in people with spasticity due to chronic stroke. dry needling is a procedure in which a thin, stainless steel needle is inserted into your skin to produce a muscle twitch response. it is intended to release a knot in your muscle and relieve pain. the total study duration is 2 days. the first visit will take about 3 hours, during which dry needling will take place, and the second visit will take about 1 hour. during both visits you will be asked to participate in examinations of reflexes (muscle responses to non-invasive nerve stimulation) and arm/leg function.


Eligibility criteria:
inclusion criteria: for adults with no known neurological conditions: * ≥18 years old * no known neurological injuries. for individuals after stroke: * neurologically stable for \>6 months (and \>1 yr post stroke) * medical clearance to participate * unilateral ankle and/or wrist spasticity, confirmed by modified ashworth scale (mas) \> 1 and the presence of spastic hyperreflexia exclusion criteria: * motoneuron injury (i.e. the neurons that give rise to the axons innervating the muscles) with inadequate response to stimulation * a cardiac condition ( history of myocardial infarction, congestive heart failure, pacemaker use, coronary artery disease, atrial fibrillation, congenital heart disease, uncontrolled hypertension) * a medically unstable condition (including temporary infections and pregnancy) * age \<18 years old * cognitive impairment sufficient to interfere with informed consent or successful completion of the protocol * metal allergies * needle phobias * lymphedema over a limb (due to risk of infection/cellulitis) * abnormal bleeding tendencies * compromised immune system * vascular disease * uncontrolled diabetes * history of epilepsy (as ddn generates strong somatosensory sensation) * anxiety disorders or in distress.

Keywords: dry needling nervous system central nervous system
rmn versus manual epicardial retrospective pmcf

Conditions: Ventricular Tachycardia; Premature Ventricular Contraction

Summary: retrospective registry will compare subjects who've undergone a mapping and/or ablation procedure for either ischemic ventricular tachycardia or premature ventricular contraction using an epicardial approach with either manual or remote magnetic navigation. subjects will be compared with regards to safety, efficacy and mortality.

up to 10 centers in the european union will be selected to conduct the trial. once a site is a selected, receives local ethics committee approval, and receives sponsor approval to enroll, the site will begin enrollment. all subjects must meet eligibility criteria and follow protocol and ethics committee requirements regarding informed consent prior to enrollment. once a subject is enrolled, the site may begin reviewing the subject's medical records and entering data into the electronic data capture system. once enrollment and retrospective data entry is complete at a site, a monitoring visit will occur where source data verification will occur.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * have undergone an epicardial rf mapping and/or ablation for a ventricular tachycardia (vt) as standard of care treatment using either the niobe mns or a manual approach * index procedure was conducted between july 1, 2013-present date. exclusion criteria: * na, all subjects who meet inclusion criteria may be enrolled.
rubber band ligation and mucosectomy for gastroesophageal reflux disease (gerd)

Conditions: Gastroesophageal Reflux Disease; Heartburn; Regurgitation; Dyspepsia

Summary: the purpose of this study is to determine the safety and effectiveness of two separate procedures to treat gastroesophageal reflux disease (gerd) also known as heartburn. the two therapies are: 1) a banding procedure alone using the cook® 6 shooter™ saeed multi-band ligator or 2) a banding/shaving procedure called endoscopic mucosal resection (emr) using the cook® duette™ multi-band mucosectomy device.


Eligibility criteria:
inclusion criteria: * subject is 18 years of age or older. * typical symptoms of heartburn and/or regurgitation requiring daily ppi therapy. * subject agrees to participate and signs consent form. exclusion criteria: * patient is pregnant. * patient has a hiatal hernia greater than 2cm. * presence of persistent daily solid food dysphagia, unplanned weight loss over ten pounds, esophageal bleeding, or vomiting more than once per week). * active medical condition that would preclude the subject from finishing this study. * bmi \> 39.

Keywords: gastroesophageal reflux disease heartburn regurgitation dyspepsia